Type I interferon autoantibodies in hospitalized patients with Middle East respiratory syndrome and association with outcomes and treatment effect of interferon beta‐1b in MIRACLE clinical trial
Abstract Background Type I interferons (IFNs) are essential antiviral cytokines induced upon respiratory exposure to coronaviruses. Defects in type I IFN signaling can result in severe disease upon exposure to respiratory viral infection and are associated with worse clinical outcomes. Neutralizing autoantibodies (auto‐Abs) to type I IFNs were reported as a risk factor for life‐threatening COVID‐19, but their presence has not been evaluated in patients with severe Middle East respiratory syndrome (MERS). Methods We evaluated the prevalence of type I IFN auto‐Abs in a cohort of hospitalized patients with MERS who were enrolled in a placebo‐controlled clinical trial for treatment with IFN‐β1b and lopinavir‐ritonavir (MIRACLE trial). Samples were tested for type I IFN auto‐Abs using a multiplex particle‐based assay. Results Among the 62 enrolled patients, 15 (24.2%) were positive for immunoglobulin G auto‐Abs for at least one subtype of type I IFNs. Auto‐Abs positive patients were not different from auto‐Abs negative patients in age, sex, or comorbidities. However, the majority (93.3%) of patients who were auto‐Abs positive were critically ill and admitted to the ICU at the time of enrollment compared to 66% in the auto‐Abs negative patients. The effect of treatment with IFN‐β1b and lopinavir‐ritonavir did not significantly differ between the two groups. Conclusion This study demonstrates the presence of type I IFN auto‐Abs in hospitalized patients with MERS..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Influenza and Other Respiratory Viruses - 17(2023), 3 |
| Beteiligte Personen: |
Alotaibi, Faizah [VerfasserIn] |
|---|
| Anmerkungen: |
© 2023 John Wiley & Sons Ltd |
|---|
| Umfang: |
8 |
|---|
| doi: |
10.1111/irv.13116 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY016003985 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY016003985 | ||
| 003 | DE-627 | ||
| 005 | 20231111170312.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231111s2023 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/irv.13116 |2 doi | |
| 028 | 5 | 2 | |a 2023-11-11_IRV_2023_17_3.zip.xml |
| 035 | |a (DE-627)WLY016003985 | ||
| 035 | |a (WILEY)IRV13116 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 100 | 1 | |a Alotaibi, Faizah |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Type I interferon autoantibodies in hospitalized patients with Middle East respiratory syndrome and association with outcomes and treatment effect of interferon beta‐1b in MIRACLE clinical trial |
| 264 | 1 | |c 2023 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2023 John Wiley & Sons Ltd | ||
| 520 | |a Abstract Background Type I interferons (IFNs) are essential antiviral cytokines induced upon respiratory exposure to coronaviruses. Defects in type I IFN signaling can result in severe disease upon exposure to respiratory viral infection and are associated with worse clinical outcomes. Neutralizing autoantibodies (auto‐Abs) to type I IFNs were reported as a risk factor for life‐threatening COVID‐19, but their presence has not been evaluated in patients with severe Middle East respiratory syndrome (MERS). Methods We evaluated the prevalence of type I IFN auto‐Abs in a cohort of hospitalized patients with MERS who were enrolled in a placebo‐controlled clinical trial for treatment with IFN‐β1b and lopinavir‐ritonavir (MIRACLE trial). Samples were tested for type I IFN auto‐Abs using a multiplex particle‐based assay. Results Among the 62 enrolled patients, 15 (24.2%) were positive for immunoglobulin G auto‐Abs for at least one subtype of type I IFNs. Auto‐Abs positive patients were not different from auto‐Abs negative patients in age, sex, or comorbidities. However, the majority (93.3%) of patients who were auto‐Abs positive were critically ill and admitted to the ICU at the time of enrollment compared to 66% in the auto‐Abs negative patients. The effect of treatment with IFN‐β1b and lopinavir‐ritonavir did not significantly differ between the two groups. Conclusion This study demonstrates the presence of type I IFN auto‐Abs in hospitalized patients with MERS. | ||
| 700 | 1 | |a Alharbi, Naif Khalaf |4 aut | |
| 700 | 1 | |a Rosen, Lindsey B. |4 aut | |
| 700 | 1 | |a Asiri, Ayed Y. |4 aut | |
| 700 | 1 | |a Assiri, Abdullah M. |4 aut | |
| 700 | 1 | |a Balkhy, Hanan H. |4 aut | |
| 700 | 1 | |a Al Jeraisy, Majed |4 aut | |
| 700 | 1 | |a Mandourah, Yasser |4 aut | |
| 700 | 1 | |a AlJohani, Sameera |4 aut | |
| 700 | 1 | |a Al Harbi, Shmeylan |4 aut | |
| 700 | 1 | |a Jokhdar, Hani A. Aziz |4 aut | |
| 700 | 1 | |a Deeb, Ahmad M. |4 aut | |
| 700 | 1 | |a Memish, Ziad A. |4 aut | |
| 700 | 1 | |a Jose, Jesna |4 aut | |
| 700 | 1 | |a Ghazal, Sameeh |4 aut | |
| 700 | 1 | |a Al Faraj, Sarah |4 aut | |
| 700 | 1 | |a Al Mekhlafi, Ghaleb A. |4 aut | |
| 700 | 1 | |a Sherbeeni, Nisreen Murad |4 aut | |
| 700 | 1 | |a Elzein, Fatehi Elnour |4 aut | |
| 700 | 1 | |a AlMutairi, Badriah M. |4 aut | |
| 700 | 1 | |a Al‐Dawood, Abdulaziz |4 aut | |
| 700 | 1 | |a Abdullah, Mashan L. |4 aut | |
| 700 | 1 | |a Barhoumi, Tlili |4 aut | |
| 700 | 1 | |a Alenazi, Mohammed W. |4 aut | |
| 700 | 1 | |a Almasood, Abdulrahman |4 aut | |
| 700 | 1 | |a Holland, Steven M. |4 aut | |
| 700 | 1 | |a Arabi, Yaseen M. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Influenza and Other Respiratory Viruses |g 17(2023), 3 |w (DE-627)WLY007586981 |x 17502659 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2023 |g number:3 |g extent:8 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2023 |e 3 |g 8 | ||